Nantahala Capital Management - Q2 2023 holdings

$1.03 Billion is the total value of Nantahala Capital Management's 124 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 37.1% .

 Value Shares↓ Weighting
IWM SellISHARES TRput$131,089,000
-27.2%
700,000
-30.7%
12.68%
-8.2%
ESTA SellESTABLISHMENT LABS HLDGS INC$126,464,285
-0.3%
1,843,234
-1.5%
12.23%
+25.8%
CASH BuyPATHWARD FINANCIAL INC$65,075,857
+17.1%
1,403,707
+4.8%
6.29%
+47.7%
IMAX SellIMAX CORP$50,033,460
-14.6%
2,944,877
-3.6%
4.84%
+7.8%
QURE SellUNIQURE NV$32,649,357
-47.2%
2,848,984
-7.2%
3.16%
-33.4%
LXFR SellLUXFER HLDGS PLC$31,639,537
-24.0%
2,223,439
-9.8%
3.06%
-4.1%
IMTX SellIMMATICS N.V$26,367,688
+39.0%
2,284,895
-16.9%
2.55%
+75.5%
RDVT SellRED VIOLET INC$26,074,820
+13.0%
1,267,614
-3.3%
2.52%
+42.6%
HGV BuyHILTON GRAND VACATIONS INC$20,033,542
+9.9%
440,879
+7.5%
1.94%
+38.7%
KROS SellKEROS THERAPEUTICS INC$19,975,929
-37.0%
497,161
-33.1%
1.93%
-20.5%
VMD BuyVIEMED HEALTHCARE INC$16,904,681
+9.9%
1,728,495
+8.5%
1.64%
+38.7%
LYRA BuyLYRA THERAPEUTICS INC$16,265,497
+264.4%
3,957,542
+78.2%
1.57%
+359.9%
BVS BuyBIOVENTUS INC$16,234,939
+193.3%
5,617,626
+8.6%
1.57%
+270.3%
RMR SellRMR GROUP INCcl a$16,203,476
-24.9%
699,330
-14.9%
1.57%
-5.2%
RMBL SellRUMBLEON INC$15,713,898
+65.7%
1,271,351
-18.8%
1.52%
+109.1%
CDXS SellCODEXIS INC$14,099,856
-33.9%
5,035,663
-2.2%
1.36%
-16.5%
GDEN SellGOLDEN ENTMT INC$13,880,233
-9.7%
332,063
-6.0%
1.34%
+13.9%
PTON SellPELOTON INTERACTIVE INC$13,552,172
-51.4%
1,762,311
-28.3%
1.31%
-38.6%
TBBK NewBANCORP INC DEL$13,319,437407,946
+100.0%
1.29%
RH  RHcall$13,183,600
+35.3%
40,0000.0%1.28%
+70.7%
MAX BuyMEDIAALPHA INCcl a$11,784,175
-27.6%
1,142,985
+5.2%
1.14%
-8.7%
DHX SellDHI GROUP INC$11,605,658
-12.4%
3,030,198
-11.3%
1.12%
+10.5%
IWM SellISHARES TRrussell 2000 etf$10,612,965
-68.9%
56,672
-70.3%
1.03%
-60.7%
CRMT BuyAMERICAS CAR-MART INC$10,594,441
+108.8%
106,178
+65.7%
1.02%
+163.5%
AUTL SellAUTOLUS THERAPEUTICS PLCspon ads$10,167,843
-28.2%
4,272,203
-44.5%
0.98%
-9.3%
SellAURA BIOSCIENCES INC$9,921,064
+26.8%
803,325
-4.8%
0.96%
+59.8%
 DARIOHEALTH CORP$9,698,212
-2.7%
2,418,5070.0%0.94%
+22.8%
IWM NewISHARES TRcall$9,363,50050,000
+100.0%
0.90%
MLHR SellMILLERKNOLL INC$8,984,511
-53.0%
607,883
-34.9%
0.87%
-40.6%
BXMT NewBLACKSTONE MTG TR INCput$8,324,000400,000
+100.0%
0.80%
HLF  HERBALIFE LTDcall$7,944,000
-17.8%
600,0000.0%0.77%
+3.8%
DXPE SellDXP ENTERPRISES INC$7,779,798
-14.5%
213,672
-36.8%
0.75%
+7.9%
ILPT BuyINDUSTRIAL LOGISTICS PPTYS T$7,779,037
+101.1%
2,357,284
+87.0%
0.75%
+154.1%
PAYO BuyPAYONEER GLOBAL INC$7,757,866
-18.2%
1,612,862
+6.8%
0.75%
+3.2%
RDI SellREADING INTL INCcl a$7,646,612
-18.7%
2,885,514
-0.4%
0.74%
+2.5%
ALTG SellALTA EQUIPMENT GROUP INC$7,327,332
-26.3%
422,812
-32.6%
0.71%
-7.0%
ZM  ZOOM VIDEO COMMUNICATIONS INcall$6,788,000
-8.1%
100,0000.0%0.66%
+15.9%
SNDX SellSYNDAX PHARMACEUTICALS INC$6,763,195
-67.2%
323,134
-66.9%
0.65%
-58.6%
DYN BuyDYNE THERAPEUTICS INC$6,673,095
+223.8%
593,164
+231.6%
0.64%
+308.2%
AMRX BuyAMNEAL PHARMACEUTICALS INC$6,662,846
+858.7%
2,149,305
+329.9%
0.64%
+1115.1%
KRTX NewKARUNA THERAPEUTICS INCcall$6,505,50030,000
+100.0%
0.63%
EHTH BuyEHEALTH INC$6,432,000
+71.8%
800,000
+100.0%
0.62%
+116.7%
 VENTYX BIOSCIENCES INC$6,319,609
-2.1%
192,6710.0%0.61%
+23.4%
RMBL NewRUMBLEON INCcall$6,180,000500,000
+100.0%
0.60%
CBAY SellCYMABAY THERAPEUTICS INC$6,058,712
-61.2%
553,307
-69.1%
0.59%
-51.0%
PTON  PELOTON INTERACTIVE INCcall$5,998,200
-32.2%
780,0000.0%0.58%
-14.5%
CYTK BuyCYTOKINETICS INC$5,847,363
+453.9%
179,257
+497.5%
0.56%
+597.5%
SellABEONA THERAPEUTICS INC$5,649,577
+40.2%
1,401,880
-1.9%
0.55%
+76.7%
PNT  POINT BIOPHARMA GLOBAL INC$5,184,050
+24.6%
572,1910.0%0.50%
+57.1%
NSPR NewINSPIREMD INC$4,669,6171,860,405
+100.0%
0.45%
CDTX SellCIDARA THERAPEUTICS INC$4,476,945
-25.5%
3,961,898
-16.2%
0.43%
-5.9%
QURE  UNIQURE NVcall$4,443,042
-43.1%
387,7000.0%0.43%
-28.1%
TALS NewTALARIS THERAPEUTICS INC$4,408,1031,450,034
+100.0%
0.43%
IMAX  IMAX CORPcall$4,247,500
-11.4%
250,0000.0%0.41%
+12.0%
SSKN  STRATA SKIN SCIENCES INC$4,173,561
-10.3%
4,393,6850.0%0.40%
+13.5%
 PAR TECHNOLOGY CORPnote 2.875% 4/1$4,048,531
+0.0%
3,785,0000.0%0.39%
+26.5%
CVNA  CARVANA COcall$3,888,000
+164.8%
150,0000.0%0.38%
+232.7%
MGTA NewMAGENTA THERAPEUTICS INC$3,790,0005,000,000
+100.0%
0.37%
TELA BuyTELA BIO INC$3,607,212
+32.4%
356,092
+39.0%
0.35%
+67.0%
NewAMYLYX PHARMACEUTICALS INC$3,548,265164,500
+100.0%
0.34%
FBIO SellFORTRESS BIOTECH INC$3,514,888
-38.0%
6,390,706
-7.6%
0.34%
-21.8%
UTHR  UNITED THERAPEUTICS CORP DEL$3,465,775
-1.4%
15,7000.0%0.34%
+24.5%
IDYA SellIDEAYA BIOSCIENCES INC$3,427,710
-1.5%
145,860
-42.5%
0.33%
+24.0%
BuyJASPER THERAPEUTICS INC$3,394,696
+11.1%
2,477,880
+46.8%
0.33%
+40.2%
NDLS NewNOODLES & CO$3,380,0001,000,000
+100.0%
0.33%
OPTN BuyOPTINOSE INC$3,298,450
+17.9%
2,681,667
+84.9%
0.32%
+49.1%
IMTXW  IMMATICS N.V*w exp 07/01/202$3,234,411
+127.8%
986,1010.0%0.31%
+187.2%
AGS BuyPLAYAGS INC$3,121,698
-12.1%
552,513
+11.3%
0.30%
+11.0%
RILY  B. RILEY FINANCIAL INC$2,874,670
+62.0%
62,5200.0%0.28%
+104.4%
ENVA  ENOVA INTL INC$2,828,640
+19.6%
53,2500.0%0.27%
+51.4%
SellSOLENO THERAPEUTICS INC$2,787,818
+86.3%
649,841
-7.1%
0.27%
+134.8%
CCCC NewC4 THERAPEUTICS INC$2,750,0001,000,000
+100.0%
0.27%
FOSL NewFOSSIL GROUP INC$2,364,863920,180
+100.0%
0.23%
SRL SellSCULLY ROYALTY LTD$2,211,198
+6.3%
303,736
-2.2%
0.21%
+34.6%
PWP SellPERELLA WEINBERG PARTNERS$2,151,414
-53.2%
258,273
-48.9%
0.21%
-40.9%
 STRUCTURE THERAPEUTICS INCsponsored ads$2,078,500
+74.7%
50,0000.0%0.20%
+120.9%
AAN SellTHE AARONS COMPANY INC$1,959,408
-29.7%
138,572
-52.0%
0.19%
-11.7%
NPCE SellNEUROPACE INC$1,907,576
-3.5%
424,850
-0.3%
0.18%
+21.9%
AGLE SellAEGLEA BIOTHERAPEUTICS INC$1,847,587
+39.8%
4,101,193
-10.0%
0.18%
+77.2%
ADCT  ADC THERAPEUTICS SA$1,806,000
+10.3%
840,0000.0%0.18%
+38.9%
BuyAYTU BIOPHARMA INC$1,738,899
+185.8%
1,086,812
+300.2%
0.17%
+257.4%
EHTH BuyEHEALTH INCcall$1,632,924
+17.4%
203,100
+36.7%
0.16%
+47.7%
AVTE  AEROVATE THERAPEUTICS INC$1,629,250
-15.0%
95,0000.0%0.16%
+7.5%
RZLT  REZOLUTE INC$1,523,820
+3.1%
769,6060.0%0.15%
+30.1%
MACK SellMERRIMACK PHARMACEUTICALS IN$1,367,120
-41.8%
111,148
-41.9%
0.13%
-26.7%
NNBR NewNN INC$1,257,154526,006
+100.0%
0.12%
SBTX NewARS PHARMACEUTICALS INC$1,206,650180,097
+100.0%
0.12%
ANEB  ANEBULO PHARMACEUTICALS INC$1,201,022
-19.0%
511,0730.0%0.12%
+1.8%
SELB  SELECTA BIOSCIENCES INC$1,120,000
-19.4%
1,000,0000.0%0.11%
+0.9%
ACER SellACER THERAPEUTICS INC$1,049,367
+15.0%
1,136,416
-5.5%
0.10%
+44.3%
SGRP BuySPAR GROUP INC$955,120
+6.3%
758,032
+8.8%
0.09%
+33.3%
TNL SellTRAVEL PLUS LEISURE CO$928,465
-96.2%
23,016
-96.3%
0.09%
-95.2%
NewELICIO THERAPEUTICS INC$901,92094,939
+100.0%
0.09%
DHC SellDIVERSIFIED HEALTHCARE TR$890,129
-87.8%
395,613
-92.7%
0.09%
-84.6%
SCYX  SCYNEXIS INC$885,000
-1.7%
300,0000.0%0.09%
+24.6%
TSHA SellTAYSHA GENE THERAPIES INC$827,003
-38.8%
1,251,139
-27.4%
0.08%
-23.1%
 UNICYCIVE THERAPEUTICS INC$828,692
-39.0%
647,4160.0%0.08%
-23.1%
COGT NewCOGENT BIOSCIENCES INC$759,32364,132
+100.0%
0.07%
NewBERKSHIRE GREY INC$705,000500,000
+100.0%
0.07%
NewAPTOSE BIOSCIENCES INC$678,516146,232
+100.0%
0.07%
CVNA NewCARVANA COcl a$648,00025,000
+100.0%
0.06%
SRTS  SENSUS HEALTHCARE INC$582,901
-39.5%
185,0480.0%0.06%
-24.3%
KROS  KEROS THERAPEUTICS INCcall$494,214
-5.9%
12,3000.0%0.05%
+20.0%
TACT SellTRANSACT TECHNOLOGIES INC$353,920
-5.9%
39,500
-35.0%
0.03%
+17.2%
XGN SellEXAGEN INC$353,493
+9.7%
121,894
-8.1%
0.03%
+36.0%
 AKUMIN INC$339,634
-73.5%
1,886,8560.0%0.03%
-66.3%
LADR NewLADDER CAP CORPcl a$293,74227,073
+100.0%
0.03%
SellLUCID DIAGNOSTICS INC$276,713
-26.6%
199,074
-23.9%
0.03%
-6.9%
SellJOURNEY MED CORP$284,143
-14.8%
178,706
-15.8%
0.03%
+3.8%
 EARGO INC$266,230
+5.3%
54,0020.0%0.03%
+36.8%
BMTX  BM TECHNOLOGIES INC$236,052
-15.3%
79,2120.0%0.02%
+9.5%
SellAVALO THERAPEUTICS INC$197,563
-86.0%
556,202
-31.2%
0.02%
-82.4%
RFL  RAFAEL HLDGS INC$151,897
+34.8%
72,6780.0%0.02%
+66.7%
 EBET INC$125,721
-71.3%
1,065,4320.0%0.01%
-64.7%
NewNOGIN INC*w exp 08/26/202$111,815330,000
+100.0%
0.01%
CUE SellCUE BIOPHARMA INC$97,674
-70.7%
26,760
-71.3%
0.01%
-65.4%
NewABEONA THERAPEUTICS INCcall$80,60020,000
+100.0%
0.01%
FULC  FULCRUM THERAPEUTICS INC$70,521
+15.8%
21,3700.0%0.01%
+40.0%
NewNOGIN INC$73,91756,425
+100.0%
0.01%
 GUARDFORCE AI CO LTD*w exp 10/01/202$50,888
+64.9%
154,2050.0%0.01%
+150.0%
GAIA  GAIA INC NEWcl a$53,463
-16.9%
23,1440.0%0.01%0.0%
CBIO SellCATALYST BIOSCIENCES INC$23,838
-28.2%
67,800
-57.7%
0.00%
-33.3%
 TC BIOPHARM HOLDINGS PLC*w exp 02/08/202$10,118
-57.0%
235,2940.0%0.00%
-50.0%
IMAC SellIMAC HLDGS INC$5,931
-96.0%
53,918
-94.8%
0.00%
-90.9%
ExitQUALTEK SERVICES INC*w exp 02/14/202$0-96,244
-100.0%
0.00%
ExitLUCY SCIENTIFIC DISCOVERY IN$0-95,800
-100.0%
-0.01%
CRIS ExitCURIS INC$0-230,614
-100.0%
-0.01%
ANGN ExitANGION BIOMEDICA CORP$0-982,743
-100.0%
-0.04%
ExitHYPERFINE INC$0-368,417
-100.0%
-0.04%
IDWM ExitIDW MEDIA HLDGS INCcl b$0-822,537
-100.0%
-0.04%
LNDC ExitLIFECORE BIOMEDICAL INC$0-194,700
-100.0%
-0.06%
WNC ExitWABASH NATL CORPput$0-50,000
-100.0%
-0.09%
DAKT ExitDAKTRONICS INC$0-292,187
-100.0%
-0.13%
ExitDISC MEDICINE INC$0-89,538
-100.0%
-0.14%
KRE ExitSPDR SER TRcall$0-50,000
-100.0%
-0.17%
MED ExitMEDIFAST INC$0-30,000
-100.0%
-0.24%
ExitAPTOSE BIOSCIENCES INC$0-4,978,975
-100.0%
-0.24%
VKTX ExitVIKING THERAPEUTICS INC$0-200,700
-100.0%
-0.26%
RNG ExitRINGCENTRAL INCcl a$0-137,622
-100.0%
-0.32%
MDXG ExitMIMEDX GROUP INC$0-1,529,100
-100.0%
-0.40%
ESTA ExitESTABLISHMENT LABS HLDGS INCcall$0-100,000
-100.0%
-0.52%
ExitCVENT HOLDING CORP$0-845,000
-100.0%
-0.54%
RH ExitRH$0-36,060
-100.0%
-0.67%
AMYT ExitAMRYT PHARMA PLCsponsored ads$0-820,825
-100.0%
-0.92%
APEN ExitAPOLLO ENDOSURGERY INCcall$0-2,000,000
-100.0%
-1.52%
APEN ExitAPOLLO ENDOSURGERY INC$0-4,575,021
-100.0%
-3.48%
TA ExitTRAVELCENTERS OF AMERICA INC$0-598,210
-100.0%
-3.96%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-08-14
Signatures

The EDGAR filing(s) were signed by:

About Nantahala Capital Management

Nantahala Capital Management is a hedge fund that was founded in 2004 by Wil Harkey. The firm is headquartered in Connecticut and has additional offices in New York and North Carolina. Nantahala Capital Management primarily invests in the technology, healthcare, and consumer sectors. The firm has a long-term investment approach and seeks to identify undervalued companies with strong growth potential.

Wil Harkey serves as the CEO and Chief Investment Officer of Nantahala Capital Management. He has over 20 years of experience in the finance industry and previously worked at Goldman Sachs and Maverick Capital. In addition to Harkey, the firm's leadership team includes COO and General Counsel, David Kozak, and CFO, Michael Kozak.

Nantahala Capital Management has a strong track record of generating positive returns for its investors. The firm's flagship fund, the Nantahala Fund, has delivered an annualized return of over 20% since its inception in 2006. The firm's success can be attributed to its disciplined investment approach and focus on long-term value creation.

Overall, Nantahala Capital Management is a well-respected hedge fund with a talented leadership team and a strong track record of performance. However, as with any investment, it is important for investors to conduct their own due diligence and carefully consider the risks before investing in the firm's funds.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ISHARES TR42Q3 202327.2%
CODEXIS INC42Q3 20233.9%
PATHWARD FINANCIAL INC35Q3 20236.3%
SCIENTIFIC GAMES CORP34Q3 20225.3%
DOVER MOTORSPORTS INC34Q3 20210.5%
GOLDEN ENTMT INC33Q3 20232.1%
QAD INC32Q3 20212.6%
SCIENTIFIC GAMES CORP31Q4 20217.7%
DOLBY LABORATORIES INC31Q4 20205.6%
LINCOLN EDL SVCS CORP31Q4 20210.7%

View Nantahala Capital Management's complete holdings history.

Latest significant ownerships (13-D/G)
Nantahala Capital Management Q2 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
AYTU BIOPHARMA, INCJune 16, 20231,086,81219.7%
Acer Therapeutics Inc.February 14, 20231,226,1917.5%
Aeglea BioTherapeutics, Inc.February 14, 20234,611,3027.5%
AKUMIN INC.February 14, 20232,206,9602.5%
ALTA EQUIPMENT GROUP INC.February 14, 20231,188,9853.7%
Apollo Endosurgery, Inc.February 14, 20234,056,6279.9%
Autolus Therapeutics plcFebruary 14, 20237,782,0184.7%
Bioventus Inc.February 14, 20233,168,5745.1%
CATALYST BIOSCIENCES, INC.February 14, 2023438,0551.4%
Drive Shack Inc.February 14, 20236,500,0007.0%

View Nantahala Capital Management's complete significant-ownership history.

Latest filings
TypeFiled
42024-03-21
42024-03-15
SC 13G2024-03-11
13F-HR/A2024-02-15
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Nantahala Capital Management's complete filings history.

Compare quarters

Export Nantahala Capital Management's holdings